Abstract
Anemia is a common consequence of cancerous disease. In lung cancer its prevalence is 37.6%, and its incidence after chemotherapy treatment is 80%. It is a prognostic factor for survival and may affect the efficacy and safety of chemotherapy and radiation therapy.
Objective: To estimate the prevalence and incidence of anemia in patients with lung cancer.
Methods: retrospective study including all patients treated for lung cancer who had at least one anemic episode during 3 years.
Results: The analysis included 264 lung cancer patients with hemoglobin less than 80% of normal, anemia was found in 33.7% of patients before any treatment, and in 66.3% of those treated with chemotherapy. The median age was 62 years (<50 years old: 13.3%, ≥70 years old: 25.4%), sex ratio M / F: 10/1; 88.5% were non-small cell cancers, 60% metastatic stages. 3.4% of patients had heart disease; 6.1% renal failure; 10.6% severe COPD. It was noted that 3.8% of cases had a PS ≥2; 42.8% BMI ≤ 25 Kg / m². The first line of treatment was in 82.6% of the cases a chemotherapy based on platinum salts. The average number of cures administered was 2.8 ± 1.5. The mean hemoglobin level before chemotherapy was 12.4. The incidence of anemia increased from 18% in the first cycle to 56% in the fourth cycle of cisplatin, compared with 29.6% to 40.7% for cisplatin-free treatment. 52 patients (19.6%) were transfused from the third cycle in half of the cases. Median survival in patients with grade 1-2 anemia was 10.1 months compared to 7.6 months in patients with grade3-4 anemia.
Conclusion: Both the prevalence and incidence of anemia in lung cancer should be taken into consideration because of the strong correlation between anemia and quality of life and the prognosis of patients with.
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2822.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018